Anaheim, Calif.—A little over two years ago, the Stanford Cancer Institute launched its Cancer Genomics Program under the direction of James M. Ford, MD, a professor of medicine/oncology and genetics at Stanford University School of Medicine.
The heart of the new program was its molecular tumor board, a multidisciplinary gathering of clinicians and researchers dedicated to uncovering novel treatment strategies for patients with advanced disease using the tools of genomic analysis.
At